WO2005067905A1 - プロポフォール含有脂肪乳剤 - Google Patents
プロポフォール含有脂肪乳剤 Download PDFInfo
- Publication number
- WO2005067905A1 WO2005067905A1 PCT/JP2005/000064 JP2005000064W WO2005067905A1 WO 2005067905 A1 WO2005067905 A1 WO 2005067905A1 JP 2005000064 W JP2005000064 W JP 2005000064W WO 2005067905 A1 WO2005067905 A1 WO 2005067905A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fat emulsion
- cyclodextrin
- group
- emulsifier
- propofol
- Prior art date
Links
- 239000002960 lipid emulsion Substances 0.000 title claims abstract description 100
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 title claims abstract description 50
- 229960004134 propofol Drugs 0.000 title claims abstract description 43
- 238000002360 preparation method Methods 0.000 title abstract description 8
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 67
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 37
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims abstract description 37
- 238000000034 method Methods 0.000 claims abstract description 25
- 150000001875 compounds Chemical class 0.000 claims abstract description 20
- 150000003839 salts Chemical class 0.000 claims abstract description 14
- 239000000839 emulsion Substances 0.000 claims description 41
- 206010047095 Vascular pain Diseases 0.000 claims description 21
- 239000003921 oil Substances 0.000 claims description 20
- 235000019198 oils Nutrition 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 238000001802 infusion Methods 0.000 claims description 10
- 230000001804 emulsifying effect Effects 0.000 claims description 9
- 239000003549 soybean oil Substances 0.000 claims description 9
- 235000012424 soybean oil Nutrition 0.000 claims description 9
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical group CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 7
- 238000001990 intravenous administration Methods 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 150000003904 phospholipids Chemical class 0.000 claims description 6
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims description 4
- 150000003626 triacylglycerols Chemical class 0.000 claims description 4
- NZAQRZWBQUIBSF-UHFFFAOYSA-N 4-(4-sulfobutoxy)butane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCOCCCCS(O)(=O)=O NZAQRZWBQUIBSF-UHFFFAOYSA-N 0.000 claims description 3
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- 239000001116 FEMA 4028 Substances 0.000 claims description 3
- 229960004853 betadex Drugs 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 229940042880 natural phospholipid Drugs 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims 1
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 claims 1
- 238000002156 mixing Methods 0.000 abstract description 12
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 abstract description 5
- 229960004194 lidocaine Drugs 0.000 abstract description 5
- 230000003444 anaesthetic effect Effects 0.000 abstract 1
- 230000000699 topical effect Effects 0.000 abstract 1
- -1 polyoxyethylene Polymers 0.000 description 30
- 238000004945 emulsification Methods 0.000 description 13
- 230000001954 sterilising effect Effects 0.000 description 12
- 238000004659 sterilization and disinfection Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 241000700159 Rattus Species 0.000 description 8
- 125000000217 alkyl group Chemical group 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- 150000004671 saturated fatty acids Chemical class 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229940072271 diprivan Drugs 0.000 description 6
- 210000002969 egg yolk Anatomy 0.000 description 6
- 235000019197 fats Nutrition 0.000 description 6
- 230000036407 pain Effects 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 6
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 6
- 239000000654 additive Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- 238000001949 anaesthesia Methods 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 3
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000013329 compounding Methods 0.000 description 3
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 3
- 239000003193 general anesthetic agent Substances 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 229940067606 lecithin Drugs 0.000 description 3
- 239000003589 local anesthetic agent Substances 0.000 description 3
- 239000000932 sedative agent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- JLPULHDHAOZNQI-JLOPVYAASA-N [(2r)-3-hexadecanoyloxy-2-[(9e,12e)-octadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC JLPULHDHAOZNQI-JLOPVYAASA-N 0.000 description 2
- 239000010775 animal oil Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 125000004990 dihydroxyalkyl group Chemical group 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 235000013345 egg yolk Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
- 229940001584 sodium metabisulfite Drugs 0.000 description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000002195 soluble material Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 125000004964 sulfoalkyl group Chemical group 0.000 description 2
- 239000012929 tonicity agent Substances 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 1
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 1
- SLKDGVPOSSLUAI-PGUFJCEWSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCCCC SLKDGVPOSSLUAI-PGUFJCEWSA-N 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 1
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- LVNGJLRDBYCPGB-UHFFFAOYSA-N 1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-UHFFFAOYSA-N 0.000 description 1
- BIABMEZBCHDPBV-MPQUPPDSSA-N 1,2-palmitoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-MPQUPPDSSA-N 0.000 description 1
- BTLPCOOVNVTENY-NFYLBXPESA-N 1,3-di(octanoyloxy)propan-2-yl (9z,12z)-octadeca-9,12-dienoate Chemical compound CCCCCCCC(=O)OCC(COC(=O)CCCCCCC)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC BTLPCOOVNVTENY-NFYLBXPESA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- NEZDNQCXEZDCBI-UHFFFAOYSA-N 2-azaniumylethyl 2,3-di(tetradecanoyloxy)propyl phosphate Chemical compound CCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCC NEZDNQCXEZDCBI-UHFFFAOYSA-N 0.000 description 1
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- BTLPCOOVNVTENY-UHFFFAOYSA-N 8L8 Natural products CCCCCCCC(=O)OCC(COC(=O)CCCCCCC)OC(=O)CCCCCCCC=CCC=CCCCCC BTLPCOOVNVTENY-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- DSNRWDQKZIEDDB-GCMPNPAFSA-N [(2r)-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-[(z)-octadec-9-enoyl]oxypropyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC DSNRWDQKZIEDDB-GCMPNPAFSA-N 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- GTXJHJOCVPTNTP-MLJFYOOPSA-N dimethyl-α-cyclodextrin Chemical compound COC[C@H]([C@H]([C@@H]([C@H]1OC)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COC)[C@H]([C@@H]([C@H]3OC)O)O[C@H]3O[C@H](COC)[C@H]([C@@H]([C@H]3OC)O)O[C@H]3O[C@H](COC)[C@H]([C@@H]([C@H]3OC)O)O3)[C@H](O)[C@H]2OC)COC)O[C@@H]1O[C@H]1[C@H](O)[C@@H](OC)[C@@H]3O[C@@H]1COC GTXJHJOCVPTNTP-MLJFYOOPSA-N 0.000 description 1
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 description 1
- 229960005160 dimyristoylphosphatidylglycerol Drugs 0.000 description 1
- BPHQZTVXXXJVHI-AJQTZOPKSA-N ditetradecanoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-AJQTZOPKSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
- 229940005494 general anesthetics Drugs 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 229940099578 hydrogenated soybean lecithin Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940057917 medium chain triglycerides Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000008533 pain sensitivity Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- RWPGFSMJFRPDDP-UHFFFAOYSA-L potassium metabisulfite Chemical compound [K+].[K+].[O-]S(=O)S([O-])(=O)=O RWPGFSMJFRPDDP-UHFFFAOYSA-L 0.000 description 1
- 229940043349 potassium metabisulfite Drugs 0.000 description 1
- 235000010263 potassium metabisulphite Nutrition 0.000 description 1
- BHZRJJOHZFYXTO-UHFFFAOYSA-L potassium sulfite Chemical compound [K+].[K+].[O-]S([O-])=O BHZRJJOHZFYXTO-UHFFFAOYSA-L 0.000 description 1
- 235000019252 potassium sulphite Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229960005480 sodium caprylate Drugs 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- BYKRNSHANADUFY-UHFFFAOYSA-M sodium octanoate Chemical compound [Na+].CCCCCCCC([O-])=O BYKRNSHANADUFY-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Definitions
- the present invention relates to a propofol-containing fat emulsion in which vascular pain upon administration is reduced.
- Provophor (2,6-diisopropylphenol) is a fat-soluble substance having hypnotic properties. Provophor is hardly soluble in water and is generally prepared in the form of an oil-in-water fat emulsion which can be administered directly into blood by intravenous injection or infusion using an oily component and an emulsifier. I have. Such fat emulsions are widely used as general anesthetics, sedatives and the like (see, for example, US Pat. No. 5,714,520). As a commercially available product, for example, 1% Diprivan TM injection (AstraZeneca) is known.
- HLB10 may be further added as a stabilizer in an aqueous phase constituting a fat emulsion containing propofol.
- a technique has been proposed in which the above hydrophilic surfactant, for example, polyoxyethylene (60) castor oil and the like is present and the pH is adjusted to 3.0 to 6.5 (see JP-A-2002-179562). According to this proposed technique, destruction of the emulsion in the obtained fat emulsion can be prevented to some extent.
- the hydrophilic surfactant itself used as a stabilizer is low in safety, the obtained fat emulsion can be prevented. Emulsions are not safe There is a disadvantage.
- Patent Document 1 JP-A-2002-179562
- Patent Document 2 US Patent Application Publication No. 2003-73665
- Patent Document 3 European Patent Application Publication No. 03/063824
- Non-patent Document 1 W. Klemment, J.O.Arndt: British Journal of Anaesthesia, 1991; 67: 281-284
- Non-Patent Document 2 E.E.M.Lilley, et al, Anaesthesia, 1996; 51: 815-818
- the present inventors have conducted intensive studies and as a result, the above object can be achieved by using a propofol-containing fat emulsion in which propofol, an oil component, an emulsifier, and a cyclodextrin compound are combined in predetermined amounts. I discovered the fact.
- the present invention has been completed as a result of further research based on this knowledge.
- the present invention provides a fat emulsion, a method for producing a fat emulsion, and the like described in the following items 1 to 11.
- Provophor-containing fat emulsion with reduced vascular pain upon intravenous administration or infusion comprising 0.1-5 w / v% of provophor, 2-20 w / v% of an oily component, and an emulsifier
- cyclodextrin conjugate At least one selected compound (hereinafter, this compound is abbreviated as “cyclodextrin conjugate”). Fat emulsion containing 0.02-lw / v%.
- the oil component is at least one selected from the group consisting of natural triglycerides and synthetic triglycerides
- the emulsifier is at least one selected from the group consisting of natural phospholipids and synthetic phospholipids.
- Item 4. The fat emulsion according to Item 1.
- Item 3 The fat emulsion according to Item 2, wherein the oily component is soybean oil and the emulsifier is egg yolk lecithin.
- Item 4 The fat emulsion according to Item 1, wherein the cyclodextrin compound is at least one selected from the group consisting of 2-hydroxypropyl- ⁇ -cyclodextrin and sulfobutylether-j8-cyclodextrinca.
- the oil component is soybean oil
- the emulsifier is egg yolk lecithin
- the cyclodextrin compound is 2-hydroxypropyl-13-cyclodextrin and sulfobutylether- ⁇ -cyclodextrinca.
- Item 6 The fat according to item 1, comprising 0.5 to 3 w / v% of propofol, 3 to 10 w / v% of an oily component, 0.5 to 7 w / v% of an emulsifier, and 0.05 to 0.5 w / v% of cyclodextrin conjugate. emulsion.
- Item 7. Item 1 containing 0.5-3 w / v% of propofol, 3-10 w / v% of an oily component, 0.5-7 w / v% of an emulsifier, and 0.05-0.2 w / v% of a cyclodextrin conjugate.
- Item 8 The method for producing a fatty emulsion according to Item 1, comprising emulsifying a mixture containing propofol, an oil component and an emulsifier in water, and then adding a cyclodextrin conjugate to the obtained emulsion.
- Item 9 The method for producing a fat emulsion according to Item 1, comprising adding a mixture containing propofol, an oil component and an emulsifier to an aqueous solution in which a cyclodextrin compound is dissolved, and emulsifying the resulting mixture.
- Section 10 A method for reducing vascular pain caused by intravenous or infusion administration of a fat emulsion containing 0.1-5 w / v% of propofol, 2-20 w / v% of an oily component, and 0.4-10 w / v% of an emulsifier.
- a method further comprising the step of blending 0.02-lw / v% of the cyclodextrin conjugate in the fat emulsion.
- Item 11 Use of a cyclodextrin-conjugated product for the production of a fat emulsion containing propofol with reduced vascular pain upon intravenous or infusion administration, wherein the lipid emulsion contains propofol 0.1 -5 w / v%, an oily component 2-20 w / v%, an emulsifier 0.4-10 w / v% and a cyclodextrin conjugate 0.02-lw / v%.
- an oil component when a predetermined amount of an oil component, an emulsifier, and a cyclodextrin compound are used in combination, these components interact with each other to obtain a fat emulsion having excellent emulsification stability.
- Emulsions were completed based on the discovery of the fact that this type of conventional propofol-containing fat emulsion was inevitable. It is.
- the fat emulsion of the present invention has the following advantages.
- Provophor is a compound known to be usable as a general anesthetic, sedative and the like in the pharmaceutical field as described in, for example, JP-A-2002-179562.
- the solubility of the compound in water is considerably lower in relation to its effective dose.
- the propofol is generally present in an amount of 0.1-5 w / v% based on the total fat emulsion.
- w / v% used for the compounding amount (concentration) of each component constituting the fat emulsion of the present invention means "weight (g) of each component / total fat emulsion”. Volume means lOOmL.
- vegetable oil can be usually used as the oil component (fat).
- oil component vegetable oil
- specific examples thereof include soybean oil, cottonseed oil, rapeseed oil, sesame oil, safflower oil, corn oil, peanut oil, olive oil, coconut oil, perilla oil, castor oil and the like.
- the oily component may be a chemically synthesized triglyceride such as 2-linoleoyl-1,3-dioctanoylglycerol, for example, a medium-chain triglyceride (MCT) having 8 to 10 carbon atoms. It may be a triglyceride.
- MCT medium-chain triglyceride
- Commercial products mainly composed of powerful medium-chain triglyceride (MCT) are trade names: “COCONARD” (COCONARD TM, Kao Corporation), “ODO TM” (Nissin Oil Co., Ltd.), and “Miglyol” (Myglyol).
- TM SASOL
- Panasate Panasate TM, NOF Corporation
- the oil component is not limited to the above-described vegetable oil and medium-chain triglyceride, and may be, for example, animal oil, mineral oil, synthetic oil, essential oil, and the like.
- One of these can be used alone, or two or more can be used in combination.
- the components to be used in combination can be selected from the same group such as vegetable oils, medium-chain triglycerides, animal oils, and mineral oils.
- yolk lecithin and yolk phosphatid which are natural phospholipids
- emulsifiers typically, yolk lecithin and yolk phosphatid, which are natural phospholipids, are used. Examples thereof include zircholine, soybean lecithin, soybean phosphatidylcholine, hydrogenated egg yolk lecithin obtained by hydrogenating them, hydrogenated egg yolk phosphatidylcholine, hydrogenated soybean lecithin, hydrogenated soybean phosphatidylcholine, and the like.
- the emulsifier may be a chemically synthesized phospholipid.
- the chemically synthesized phospholipids include phosphatidylcholine (dipalmitoylphosphatidylcholine, dimyristoylphosphatidylcholine, distearoylphosphatidylcholine, dioleoylphosphatidylcholine, etc.), phosphatidylglycerol (dipalmitoylphosphatidylglycerol, dimyristoylphosphatidylglycerol, distearoylglycerol).
- phosphatidylcholine dipalmitoylphosphatidylcholine, dimyristoylphosphatidylcholine, distearoylphosphatidylcholine, dioleoylphosphatidylcholine, etc.
- phosphatidylglycerol dipalmitoylphosphatidylglycerol, dimyristoylphosphatidylglycerol, distearoylglycerol.
- emulsifiers can be used alone or in combination of two or more.
- preferred emulsifiers are egg yolk lecithin, egg yolk phosphatidylcholine, soy lecithin and soy phosphatidylcholine.
- the oil component and the emulsifier may be in the form of an emulsion in which these are mixed in advance and the mixture is emulsified in water.
- the method of preparing the emulsion (the method of emulsification and dispersion) is well known in the art. For example, a method can be employed in which water for injection is added to a mixture of the two to roughly emulsify, and then the resulting coarse emulsion is emulsified (finely emulsified) using an appropriate high-pressure emulsifier or the like.
- the coarse emulsification can be carried out using a homomixer such as TK homomixer manufactured by Tokushu Kika Kogyo Co., Ltd., usually at 5000 rpm or more for 5 minutes or more.
- Milking can be performed using a high-pressure homogenizer, an ultrasonic homogenizer, or the like.
- a high-pressure homogenizer When a high-pressure homogenizer is used, it can be generally passed through about 2 to 50 times, preferably about 5 to 20 times under a pressure condition of about 200 kg / cm 2 or more.
- These mixing and emulsifying operations may be performed by employing a slight heating operation (usually about 40 to 80 ° C) which may be performed at room temperature.
- the mixing ratio of the oil component and the emulsifier is not particularly limited as long as an emulsion can be obtained.
- the oil component is in the range of 2-20 w / v% in the fat emulsion of the present invention, preferably in the range of 3-10 w / v%
- the lipid is in the range of 0.4-10 w / v% in the fat emulsion of the present invention.
- Preferably It is present in the range of 0.5-7w / v%. Utilization within this range makes it possible to obtain a stable propofol fat emulsion in which the desired vascular pain of the present invention is prevented or reduced.
- the fat emulsion of the present invention contains at least one compound selected from the group consisting of cyclodextrin, derivatives thereof, and pharmacologically acceptable salts thereof.
- cyclodextrin refers to a cyclic oligosaccharide composed of 6-12 glucose units.
- the cyclodextrin derivative refers to a cyclodextrin in which some or all of the hydroxyl groups at positions 2, 3, and 6 of glucose constituting cyclodextrin are substituted with another functional group.
- Specific examples of the above cyclodextrin and its derivative include a compound represented by the following general formula (1).
- n is an integer of 6-12, R u , R 12 and also the same or different and are a hydrogen atom, an alkyl group, a monohydroxyalkyl group, a dihydroxyalkyl group, a sulfoalkyl group, a carboxyalkyl group or a sugar a residue.
- n pieces of R 11 are the same or different and may be O,.
- n pieces of R 12 may be different even in the same. also, the same also the n R 13 Or different.
- examples of the alkyl group include C alkyl such as methyl, ethyl and propyl.
- 1-4 killing groups can be exemplified.
- Examples of the monohydroxyalkyl group include monohydroxy-C alkyl groups such as hydroxymethyl, 2-hydroxyethyl and 2-hydroxypropyl.
- dihydroxyalkyl group for example, dihydroxymethyl
- dihydroxy-C alkyl groups such as 2,2-dihydroxyethyl and dihydroxypropyl
- sulfoalkyl group examples include sulfo-C 1 -alkyl groups such as sulfomethyl, 2-sulfoethyl, and sulfobutyl.
- alkyl group examples include a carboxy-C alkyl group such as carboxymethyl and 2-carboxyethyl.
- sugar residue for example, darkosyl
- alkyl derivatives of cyclodextrin include dimethyl- ⁇ -cyclodextrin, dimethyl- ⁇ -cyclodextrin, dimethyl- ⁇ -cyclodextrin, and the like.
- Hydroxyalkyl derivatives of cyclodextrin include 2-hydroxypropyl- ⁇ -cyclodextrin, 2-hydroxypropyl-j8-cyclodextrin, 2-hydroxypropyl- ⁇ -cyclodextrin, and the like.
- Sulfoalkyl ether derivatives of cyclodextrin include sulfobutyl ether- di -cyclodextrin, sulfobutyl ether- / 3-cyclodextrin, sulfobutyl ether- ⁇ -cyclodextrin and the like.
- Sugar bond derivatives of cyclodextrin include darcosyl- ⁇ -cyclodextrin, darcosyl-j8-cyclodextrin, dalcosyl- ⁇ -cyclodextrin, maltosyl- ⁇ -cyclodextrin, maltosyl- ⁇ -cyclodextrin, maltosyl-y-cyclo Dextrin and the like. Of these, 2-hydroxypropyl-j8-cyclodextrin and sulfobutylether-13-cyclodextrin are particularly preferred! /.
- Examples of pharmacologically acceptable salts of cyclodextrin and its derivatives include, for example, sodium salt, potassium salt, magnesium salt and the like.
- the compounding amount of the cyclodextrin conjugate in the fat emulsion of the present invention is generally in the range of about 0.02-lw / v%, preferably in the range of about 0.05-0.5w / v%, more preferably in the range of about 0.05-0.5w / v%. Range force of about 0.2w / v% Can be selected appropriately. Within this range, the cyclodextrin By blending, it is possible to obtain a propofol fat emulsion exhibiting the desired effects of the present invention without lowering the safety of the obtained fat emulsion.
- the propofol-containing fat emulsion of the present invention or the emulsion used for the preparation thereof is not particularly required, but if necessary, appropriate amounts of various additives known to be able to be added and blended into this kind of fat emulsion. Can be further added and blended.
- the additive include an antioxidant, an antibacterial agent, a pH adjuster, and a tonicity agent.
- Specific examples of the antioxidant include sodium metabisulfite (which also acts as an antibacterial agent), sodium sulfite, sodium bisulfite, potassium metabisulfite, potassium sulfite, and sodium thiosulfate.
- the antibacterial agent examples include sodium caprylate, methyl benzoate, sodium metabisulfite (which also acts as an antioxidant), sodium edetate, and the like.
- As the pH adjuster hydrochloric acid, acetic acid, lactic acid, malic acid, citric acid, sodium hydroxide, and the like can be used.
- As the tonicity agent glycerin; sugars such as glucose, fructose and maltose; sugar alcohols such as sorbitol and xylitol can be used.
- the oil-soluble material can be used by previously mixing it with the oily component constituting the emulsion.
- the water-soluble material can be mixed with water for injection, or added to the aqueous phase of the obtained emulsion. The amounts of these additives are obvious to those skilled in the art, and do not differ from those conventionally known.
- a stabilizer for improving emulsion stability can be added to the propofol-containing fat emulsion of the present invention and the emulsion for preparing the same.
- the stabilizer includes a general surfactant and the like.
- the surfactants include the substances described in the following (a) to (c), which the present inventors have newly found a stabilizing effect on this kind of fat emulsion (International Publication No. 2004/2004). / 052354 pamphlet). The description of this document is incorporated herein by reference.
- Fatty acid strength obtained by esterification to a glycerol moiety is a linear or branched saturated or unsaturated fatty acid having 10-22 carbon atoms, preferably a straight-chain or branched saturated fatty acid having 12-18 carbon atoms.
- a phospholipid derivative which is a linear or branched saturated or unsaturated fatty acid having 14 to 18 carbon atoms,
- the fat emulsion of the present invention is prepared by mixing and emulsifying a predetermined amount of the above-mentioned propofol, an oily component, an emulsifier, a cyclodextrin compound, and additives to be added as required.
- a particularly preferred combination of each component is that the oily component is soybean oil, the emulsifier is egg yolk lecithin, and the cyclodextrin compound is 2-hydroxypropyl- ⁇ -cyclodextrin and sulfobutyl ether-j8-cyclohexane. There may be mentioned at least one combination in which a group strength composed of dextrin is also selected.
- the method of mixing and emulsifying each component is not particularly limited as long as an emulsion is obtained, and can be carried out according to a general method.
- a mixture containing propofol, an oil component and an emulsifier is emulsified in water, and the resulting emulsion is added with a cyclodextrin conjugate.
- the desired fat emulsion of the present invention can be obtained by the addition method.
- a method of adding a mixture containing propofol, an oil component and an emulsifier to an aqueous solution in which a cyclodextrin compound is dissolved in water, and emulsifying the resulting mixture may also be used to emulsify the desired fat of the present invention.
- An emulsion can be obtained.
- provophor and a cyclodextrin conjugate are added to this fat emulsion, and the resulting mixture is emulsified to emulsify the mixture.
- the desired fat emulsion of the invention can be obtained.
- Means for obtaining an emulsion that can be employed in each of the above methods are well known in the art.
- a homomixer such as TK homomixer manufactured by Tokushu Kika Kogyo Co., Ltd.
- a coarse emulsification method that usually requires 5000 rotations or more for 5 minutes or more
- a fine emulsification method using a high-pressure homogenizer or ultrasonic homogenizer are used. can do .
- the fine emulsification using a high-pressure homogenizer can be generally carried out under a pressure condition of about 200 kg / cm 2 or more by passing about 2 to 50 times, preferably about 5 to 20 times.
- each milking operation should be carried out using a slight heating operation (usually around 55-80 ° C) that can be carried out at room temperature.
- the fat emulsion of the present invention obtained by force can be adjusted to a desired pH as needed, and then filtered and sterilized according to a conventional method to give a product.
- the pH of the propofol-containing fat emulsion of the present invention can be adjusted to usually about 5.0-9.0, preferably about 6.0-8.0.
- Filtration can be performed using a normal membrane filter. Sterilization can be performed, for example, by high-pressure steam sterilization, hot water immersion sterilization, shower sterilization, or the like. A more preferable sterilization operation is, for example, high-pressure steam sterilization using an autoclave (for example, at 121 ° C for 12 minutes).
- the present invention also relates to a method for reducing blood vessel pain by injection or infusion of a propofol-containing fat emulsion, wherein the fat emulsion contains 0.02-lw / v% of a cyclodextrin conjugate.
- This method can be carried out in the same manner as the above-described method for preparing the fat emulsion of the present invention, that is, the method of mixing and emulsifying the components.
- the present invention further provides the use of a cyclodextrin compound for producing the provophor-containing fat emulsion of the present invention.
- the fat emulsion of the present invention is based on the fact that a predetermined amount of each of propofol, an oil component, an emulsifier and a cyclodextrin compound is used in combination, and in particular, that a predetermined amount of a cyclodextrin compound is blended. It can produce an effect that can significantly reduce the occurrence of vascular pain upon administration.
- the fat emulsion of the present invention has high safety and features. Te ru.
- the fat emulsion of the present invention is excellent in emulsification stability, in particular, emulsification stability against a change in temperature. That is, when the fat emulsion of the present invention is subjected to a heat sterilization operation such as high-pressure steam sterilization, the emulsion stability is maintained without impairing the emulsion stability.
- the average particle size of the fat particles constituting the present invention fat emulsion is as fine as about 0.3 ⁇ m or less, and has a feature that the particle size does not substantially change before and after sterilization.
- the above excellent milk stability is maintained even after long-term storage (for example, 6 months at 40 ° C).
- the fat emulsion of the present invention not only maintains excellent emulsification stability for a long period of time, but also reduces the activity of propofol, an active ingredient, by the above-mentioned carothermal sterilization operation and subsequent long-term storage. It also has an excellent feature that it does not.
- the present inventors have confirmed that the activity of this propofol does not substantially decrease, for example, when the fat emulsion of the present invention is stored at 40 ° C. for 6 months.
- FIG. 1 is a graph showing the degree of alleviation of vascular pain observed when the propofol-containing fat emulsion of the present invention is administered.
- a fat emulsion of the present invention (total amount 100 mL) having each component strength shown in Table 2 below was prepared as follows. [Table 2]
- Soybean oil (refined soybean oil; Nisshin Oil Co., Ltd.)
- the coarse emulsion was subjected to an emulsification temperature of 40 to 80 ° C. and an emulsification pressure of 550 kg / min under a nitrogen stream until the average particle diameter became 0.3 ⁇ m or less.
- the emulsion was finely emulsified in cm 2 .
- the obtained fat emulsion shows no crystal precipitation even after high-pressure steam sterilization in a pH range of 5-8, and has excellent emulsion stability.
- the emulsion emulsion has a particle size of about 200 nm. Yes, It was finely proportioned.
- the test was performed as follows. That is, 7- to 9-week-old male SD rats were divided into four groups, rats of each group (three rats per group) were anesthetized with urethane, and the right hind limb surgical field and the electrode insertion area were shaved and placed in a dorsal position. Fixed. A polyethylene catheter was placed in the right posterior abdominal wall artery for administration of a fat emulsion sample, and then kept in a prone position in a Bowlman cage. A concentric needle electrode and an indifferent electrode for electromyogram measurement were placed on the right hind limb, and guided to a biological amplifier (AB-621G, Nihon Kohden).
- the electromyogram measurement was performed before the administration of the fat emulsion sample. After 1 hour or more after the operation and the electromyogram waveform was stabilized, 0.05 mL of 1% Diprivan TM injection was administered from an indwelling polyethylene catheter, and the electromyogram was measured after administration, and the peak of the electromyogram was measured. The area was calculated (this value is used as the reference value).
- the propofol fat emulsion of the present invention is superior in its safety without impairing the emulsion stability, and has the ability to prevent or reduce the occurrence of pain upon administration, such as a general anesthetic and a sedative. It is useful as a medicine.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Anesthesiology (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/585,311 US20090192230A1 (en) | 2004-01-14 | 2005-01-06 | Propofol-containing fat emulsion preparation |
EP05703332A EP1704858A4 (en) | 2004-01-14 | 2005-01-06 | PROPOFOL-CONTAINING FAT-EMULSION PREPARATION |
JP2005517008A JPWO2005067905A1 (ja) | 2004-01-14 | 2005-01-06 | プロポフォール含有脂肪乳剤 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004006409 | 2004-01-14 | ||
JP2004-006409 | 2004-01-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005067905A1 true WO2005067905A1 (ja) | 2005-07-28 |
Family
ID=34792141
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/000064 WO2005067905A1 (ja) | 2004-01-14 | 2005-01-06 | プロポフォール含有脂肪乳剤 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20090192230A1 (ja) |
EP (1) | EP1704858A4 (ja) |
JP (1) | JPWO2005067905A1 (ja) |
KR (1) | KR20060130646A (ja) |
CN (1) | CN1909893A (ja) |
TW (1) | TW200529881A (ja) |
WO (1) | WO2005067905A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006112276A1 (ja) * | 2005-04-13 | 2006-10-26 | Otsuka Pharmaceutical Factory, Inc. | プロポフォール含有脂肪乳剤 |
US11992483B2 (en) | 2021-03-31 | 2024-05-28 | Cali Biosciences Us, Llc | Emulsions for local anesthetics |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101199480B (zh) * | 2007-12-11 | 2010-07-28 | 西安力邦医药科技有限责任公司 | 一种含镇痛药的复方丙泊酚脂肪乳注射剂及制备方法 |
EP2106786A1 (de) * | 2008-04-04 | 2009-10-07 | Roewer, Norbert, Univ.-Prof. Dr. med. | Pharmazeutische Zubereitung mit permethyliertem Cyclodextrin |
DE102009003980A1 (de) | 2009-01-07 | 2010-07-08 | B. Braun Melsungen Ag | Propofol in triheptanoinhaltiger Trägeremulsion |
WO2010148288A2 (en) * | 2009-06-19 | 2010-12-23 | Lyotropic Therapeutics, Inc. | Pharmaceutical formulations with low aqueous levels of free unbound drug |
CN102085185B (zh) * | 2010-12-07 | 2013-04-24 | 西安力邦制药有限公司 | 无痛和低注射刺激的新型丙泊酚脂肪乳制剂配方和制备方法 |
US9925274B2 (en) | 2012-11-15 | 2018-03-27 | Sapiotec Gmbh | Delphinidin complex as an antiphlogistic or immunosuppressive active ingredient |
CA2893883A1 (en) | 2012-12-11 | 2014-06-19 | Sapiotec Gmbh | Delphinidin for combating melanoma cells |
CN109985001A (zh) * | 2017-12-29 | 2019-07-09 | 北京蓝丹医药科技有限公司 | 一种注射用营养型脂肪乳及其制备方法 |
CN110638755B (zh) * | 2019-10-29 | 2021-05-11 | 江苏盈科生物制药有限公司 | 丙泊酚中长链脂肪乳及其制备方法 |
CN113712917A (zh) * | 2021-09-26 | 2021-11-30 | 远大生命科学(武汉)有限公司 | 一种丙泊酚中长链脂肪乳注射液及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06128149A (ja) * | 1992-09-04 | 1994-05-10 | Japan Tobacco Inc | 水溶性物質を含有してなるw/o型エマルジョン及び油剤 |
WO1996032135A1 (en) * | 1995-04-10 | 1996-10-17 | Farmarc Nederland Bv Of Citco Trust International Management (T.I.M.) B.V. | Pharmaceutical composition |
WO2002074200A1 (en) * | 2001-03-20 | 2002-09-26 | Cydex, Inc. | Formulations containing propofol and a sulfoalkyl ether cyclodextrin |
JP2005022989A (ja) * | 2003-06-30 | 2005-01-27 | Otsuka Pharmaceut Factory Inc | 可溶化または分散化された難溶性化合物を含む組成物 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IN187686B (ja) * | 2000-06-21 | 2002-06-08 | Bharat Serums & Vaccines Ltd | |
JP2002179562A (ja) * | 2000-12-14 | 2002-06-26 | Towa Yakuhin Kk | 安定な静注用無痛プロポフォール脂肪乳剤 |
US7034013B2 (en) * | 2001-03-20 | 2006-04-25 | Cydex, Inc. | Formulations containing propofol and a sulfoalkyl ether cyclodextrin |
-
2005
- 2005-01-06 US US10/585,311 patent/US20090192230A1/en not_active Abandoned
- 2005-01-06 JP JP2005517008A patent/JPWO2005067905A1/ja active Pending
- 2005-01-06 KR KR1020067015725A patent/KR20060130646A/ko not_active Application Discontinuation
- 2005-01-06 EP EP05703332A patent/EP1704858A4/en not_active Withdrawn
- 2005-01-06 CN CNA2005800023731A patent/CN1909893A/zh active Pending
- 2005-01-06 WO PCT/JP2005/000064 patent/WO2005067905A1/ja active Application Filing
- 2005-01-11 TW TW094100734A patent/TW200529881A/zh unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06128149A (ja) * | 1992-09-04 | 1994-05-10 | Japan Tobacco Inc | 水溶性物質を含有してなるw/o型エマルジョン及び油剤 |
WO1996032135A1 (en) * | 1995-04-10 | 1996-10-17 | Farmarc Nederland Bv Of Citco Trust International Management (T.I.M.) B.V. | Pharmaceutical composition |
WO2002074200A1 (en) * | 2001-03-20 | 2002-09-26 | Cydex, Inc. | Formulations containing propofol and a sulfoalkyl ether cyclodextrin |
JP2005022989A (ja) * | 2003-06-30 | 2005-01-27 | Otsuka Pharmaceut Factory Inc | 可溶化または分散化された難溶性化合物を含む組成物 |
Non-Patent Citations (1)
Title |
---|
See also references of EP1704858A4 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006112276A1 (ja) * | 2005-04-13 | 2006-10-26 | Otsuka Pharmaceutical Factory, Inc. | プロポフォール含有脂肪乳剤 |
US11992483B2 (en) | 2021-03-31 | 2024-05-28 | Cali Biosciences Us, Llc | Emulsions for local anesthetics |
Also Published As
Publication number | Publication date |
---|---|
JPWO2005067905A1 (ja) | 2007-12-27 |
US20090192230A1 (en) | 2009-07-30 |
TW200529881A (en) | 2005-09-16 |
CN1909893A (zh) | 2007-02-07 |
EP1704858A4 (en) | 2008-06-04 |
EP1704858A1 (en) | 2006-09-27 |
KR20060130646A (ko) | 2006-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005067905A1 (ja) | プロポフォール含有脂肪乳剤 | |
TWI376239B (en) | Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof | |
JP5704787B2 (ja) | 液体生物活性物質の固体配合物 | |
JP2019206571A (ja) | ナノエマルジョン送達系の組成物 | |
WO2009012718A1 (fr) | Émulsifiant composite, émulsion préparée à partir de celui-ci et procédé de préparation de celle-ci | |
US20090069445A1 (en) | Propofol-containing fat emulsions | |
JP4929158B2 (ja) | 難水溶性薬物を含有する医薬組成物 | |
JP2008514720A (ja) | タキソイドおよび他の不溶性薬物を送達するための低油乳剤組成物 | |
KR20140131936A (ko) | 크릴 인지질을 포함하는 호르몬 함유 유화액 | |
WO2002009667A2 (de) | Dispersionen zur formulierung wenig oder schwer löslicher wirkstoffe | |
JPH0899867A (ja) | 眼科用ビヒクルとして有用な水中油型ナノエマルジョンおよびその調製法 | |
EP2491919B2 (en) | Pharmaceutical solution of taxanes comprising ph regulator and preparation method thereof | |
WO1997009986A1 (fr) | Preparation lyophilisee contenant de la pge1 et son procede de production | |
JP2007505040A (ja) | 水溶性ジテルペンの調製方法およびその適用 | |
AU2019231699B2 (en) | Aqueous formulations for insoluble drugs | |
JPH0157096B2 (ja) | ||
EP0233849A1 (en) | Composition of pregnanolole comprising a stable oil-in-water emulsion | |
JP2005225818A (ja) | パクリタキセル又はドセタキセルの医薬組成物 | |
Jug | Cyclodextrin-based drug delivery systems | |
JP2019510048A (ja) | 週1回又は隔週1回の投与に適したリラグルチドの粘弾性ゲル | |
JPH10510267A (ja) | スフィンゴ脂質の投与に適したエマルジョン及びその使用 | |
WO2005065676A1 (ja) | パクリタキセルまたはドセタキセルを含む脂肪乳剤 | |
JP2005075783A (ja) | 難溶性化合物の可溶化または分散化用組成物 | |
JP2828655B2 (ja) | 脂溶性薬物含有水性液 | |
JPH08505400A (ja) | 生体に作用するステロイドを含有する製薬用エマルジョン |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005517008 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10585311 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580002373.1 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005703332 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067015725 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2005703332 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067015725 Country of ref document: KR |